

Prescription of nutritional interventions to HIV patients in Dar es Salaam, Tanzania

Ajibola I Abioye¹, Hellen Siril², Aisa Mhalu², Nzovu Ulenga, Wafaie W Fawzi^{1, 3, 4}

¹*Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston MA, USA*

²*Management and Development for Health (MDH), Dar es Salaam, Tanzania*

³*Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston MA, USA*

⁴*Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston MA, USA*

Correspondence to: Ajibola Ibraheem Abioye, Harvard T.H. School of Public Health, 677 Huntington Ave, Boston, Massachusetts 02115, USA; Phone: 617-432-1528; Email: iaa551@g.harvard.edu

Number of words in manuscript – Number of figures: Number of tables:

Running Title: Iron supplements in HIV

Abbreviations used in text:

AIDS: Acquired Immune Deficiency Syndrome; ART: Antiretroviral therapy; BMI: Body Mass Index; CI: Confidence Interval; HAART: Highly Active Antiretroviral Therapy; HIV: Human Immunodeficiency Virus; ID: Iron deficiency; IDA: Iron deficiency anemia; IQR: Interquartile range; PLHIV: People living with HIV; RR: Relative risk; TB: Tuberculosis;

Authors' names for Pubmed indexing: Abioye AI, Siril H, Mhalu A, Ulenga N, Fawzi WW

Conflict of Interest Disclosures: None of the authors have any conflict of interest.

Funding: None

1 Abstract

2 Background

3 Anemia and micronutrient deficiencies are common among people living with HIV (PLHIV). There are no
4 current guidelines from the World Health Organization (WHO) regarding whether supplements are
5 recommended or not. We sought to assess the practices with respect to nutritional supplementation
6 among clinicians providing care to people living with HIV in Dar es Salaam, Tanzania.

7 Methods

8 We conducted a cross-sectional survey at clinics providing care to PLHIV in Dar es Salaam, Tanzania. All
9 healthcare workers with prescribing responsibility were invited. Self-administered questionnaires were
10 used to collect information about participants' demographic and professional characteristics, and their
11 approach to making decisions regarding the prescription of nutritional interventions. Descriptive
12 analyses regarding prescribing patterns and associated factors were done.

13 Results

14 Two hundred and fifty-four clinicians participated in the survey. They were clinical officers (65%),
15 medical assistants (21%) or medical doctors (13%), and attended to 30 patients (IQR: 10, 100) on
16 average, per week. While the majority usually prescribed iron and multivitamin supplements (79% and
17 76%, respectively), only 33% usually prescribed ready-to-use therapeutic foods (RUTF). The decision to
18 prescribe nutritional supplements were typically guided by patients' clinical condition and laboratory
19 test results. Pallor was the most commonly considered clinical feature across patient subgroups. Most
20 participants commenced supplementation when hemoglobin concentration was ≤ 10 g/dl. Clinicians who
21 attended to between 10 and <100 patients or believed in the need for universal iron supplementation
22 for pregnant PLHIV were more likely to prescribe iron supplements compared to counterparts who

23 attended to <10 patients weekly or who did not believe in the need for universal iron supplementation
24 for pregnant PLHIV respectively.

25 Conclusion

26 Clinicians frequently prescribe nutritional supplements, with considerable variation in how they decide
27 whether and how to.

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42 Introduction

43 Mortality among people living with HIV (PLHIV) has declined considerably in the last 15
44 years, due to wider access to highly active antiretroviral therapy (HAART) regimens^(1; 2). Despite
45 this tremendous progress, 7 – 13% of HIV-infected patients in sub-Saharan African countries
46 still die in the first year of HAART^(3; 4; 5). Evidence among pre-HAART and HAART era suggests
47 that poor nutrition is likely to be partly responsible for the slow decline in mortality rates. For
48 instance, anemia is very common among PLHIV, with a prevalence of 85% in some settings, and
49 iron deficiency is responsible for a considerable proportion of cases^(6; 7). Anemia is associated
50 with a greater risk of all-cause mortality, disease progression, and tuberculosis treatment
51 failure^(8; 9; 10). Micronutrient deficiencies are also common. Eighty-six percent of participants in
52 one cross-country study had at least one micronutrient deficiency and 57% had deficiencies of
53 two or more micronutrients⁽¹¹⁾. Micronutrient deficiencies are also associated with higher risk
54 of HIV disease progression, treatment failure, and mortality^(12; 13; 14). Micronutrients reduce
55 oxidative stress and improve the production of immune cells and antibodies, thereby protecting
56 the integrity of the oral and gastrointestinal mucosa, enhancing systemic immune function, and
57 reducing viral replication^(13; 15; 16).

58 The current guidelines from the World Health Organization (WHO) neither recommends
59 nor discourages the use of multivitamin or iron supplements⁽¹⁷⁾. This is partly due to the
60 significant equipoise regarding the safety and effectiveness of some of these interventions. Iron
61 supplementation is well-known to prevent and treat anemia in the general population, and is
62 recommended to pregnant women including HIV-infected pregnant women⁽¹⁷⁾. Iron
63 supplementation is however potentially harmful in the context of infections and a recent large

64 cohort study in Tanzania reported that the risk of mortality among patients who received iron
65 supplementation at initiation of ART may be as high as 3.8 to 6.3-fold⁽¹⁸⁾. This risk arises
66 because elevated iron status, determined by serum ferritin measurement, has been shown to
67 be associated with a 2 – 3 fold greater risk of all-cause mortality^(19; 20). RCTs^(21; 22; 23; 24) that have
68 examined the impact of iron supplement use have tended to have small sample sizes, but have
69 reported significant reduction in anemia and iron deficiency⁽²³⁾, improvement in immunologic
70 status⁽²³⁾, but no effect on viral load⁽²²⁾. In the pre-ART era, large randomized trials
71 demonstrated that multivitamin supplementation improved the risk of hematologic outcomes,
72 disease progression and death^(13; 25), and a recent prospective cohort study among PLHIV on
73 HAART also found that multivitamin supplementation may be protective⁽²⁶⁾.

74 Anecdotal information suggests that clinicians continue to prescribe these nutritional
75 interventions, but poor supply chain management and stock-outs have been important barriers
76 to access ⁽²⁷⁾. Understanding the extent of use of iron and multivitamin supplements may guide
77 the design of large well-powered studies to re-examine the safety and effectiveness of these
78 interventions in the context of HAART. We conducted a cross-sectional study to investigate the
79 prescription patterns of micronutrient supplements among clinicians providing care to people
80 living with HIV in Dar es Salaam, Tanzania. The specific objectives were to describe the reasons
81 that clinicians providing care to PLHIV commence and discontinue nutritional interventions, to
82 clarify the role of biomarker testing to guide the commencement and discontinuation of
83 nutritional interventions at HIV Care and Treatment clinics in Dar es Salaam, Tanzania, and to
84 identify barriers to the provision of nutritional interventions at HIV Care and Treatment clinics
85 in Dar es Salaam, Tanzania

86 **Methods**

87 **Study location and participants**

88 The study was conducted at HIV care and treatment clinics (CTC) and Prevention of Mother to
89 Child Transmission of HIV (PMTCT) clinics in Dar es Salaam between November and December 2020. The
90 Management and Development for Health (MDH), Dar es Salaam, Tanzania provides operational support
91 to these clinics to facilitate the care of PLHIV in Dar es Salaam. Participants in the study were health
92 workers with prescribing responsibility at these clinics. Therefore, physicians and medical assistants will
93 be invited to participate. There are approximately 200 clinics providing care to PLHIV in Dar es Salaam.

94 **Study design**

95 This was a cross-sectional study among clinicians and medical assistants who directly provide
96 care to PLHIV at the selected MDH-supported clinics across Dar es Salaam. All eligible clinicians would be
97 invited to participate.

98 Given that there are no prior studies that have examined prescribing patterns for nutritional
99 supplementation among PLHIV, we assumed a prevalence of 50% and a precision of 5%, in a population
100 of approximately 300 eligible clinicians. We determined that an estimated sample size of 152 will suffice.
101 The desired sample size for the study was therefore 183, to allow for 20% non-response.

102 **Study procedures**

103 Study personnel approached physicians with informed consent forms written in Kiswahili, the
104 language Tanzanians most commonly converse in, with copies in English for those who may prefer it.
105 The consent forms provided detailed explanation of the purpose of the study, the approach to data
106 collection, and their freedom to participate or otherwise. Following consenting, data was collected using
107 netbooks or smartphones, on which an anonymous Qualtrics web survey form had been loaded. The

108 study supervisor used a list of all physicians with active employment at these clinics to track the
109 distribution and retrieval of paper copies of informed consent forms and study questionnaires. No
110 identifiable data were collected on the questionnaires, and there was no record linking the individual
111 physician to the study questionnaire.

112 Study Instrument

113 The study questionnaire was in 4 sections. Section 1 had questions about participants'
114 demographic and professional characteristics. This section collected information on participants' district,
115 facility type, age, professional qualification (clinical officer, medical assistant or medical doctor), time
116 since graduation (years), and a self-reported estimate of the number of patients attended to in the
117 previous week. Sections 2 – 4 had similar questions, repeated for iron supplements, multivitamin
118 supplements and ready-to-use therapeutic foods (RUTF). These sections had questions about whether
119 nutritional interventions were usually prescribed, the frequency of prescription in the past week, the
120 usual dose of prescription, and questions exploring the reasons for prescribing the nutritional
121 interventions. Additional questions asked about hemoglobin testing practices to initiate or discontinue
122 nutritional interventions, as well as barriers to prescribing the supplements.

123 Statistical Analysis

124 The distribution of participants' demographic and professional characteristics were described
125 using frequency and percentages for categorical variables, and medians (with interquartile range (IQR))
126 for continuous variables. The responses to questions in sections about prescription practices were
127 described using frequency and percentages, for each of iron supplements, multivitamin supplements
128 and ready-to-use therapeutic foods (RUTF). Univariate log-binomial regression models estimated the
129 probability that clinicians self-report prescribing nutritional interventions in relation to demographic and
130 professional characteristics. Models were not adjusted for any covariates.

131 93% of participants had complete data on the demographic and professional characteristics, but
132 there was substantial item missingness. No imputation was done for item missingness, and the number
133 of respondents are, instead, reported for all items.

134 Institutional ethical clearance

135 Institutional ethical clearance was obtained from the Tanzania National Institute of Medical
136 Research (NIMR) and the Harvard T.H. Chan School of Public Health's (HSPH) Institutional Review Board.
137 The Tanzania National Institute of Medical Research (NIMR) regulates the conduct of medical and public
138 health research in Tanzania.

139

140 Results

141 Two hundred and fifty-four clinicians participated in our survey (**Table 1**). Most were clinical
142 officers (65%), and the others were medical assistants (21%) or medical doctors (13%). They worked at
143 facilities at all five districts in Dar es Salaam: Kinondoni (31%), Ilala (26%), Temeke (26%), Ubungo (13%)
144 and Kigamboni (3%); and there were mostly at care and treatment (CTC) facilities (64%). The median
145 (IQR) age of the participants was 43 (34, 49), and most were >40 y (62%). The time since they graduated
146 was 13 years (IQR: 5, 21), on average, and they had been working at the MDH for 5 years (IQR: 2, 11), on
147 average. The clinicians attended to 30 patients (IQR: 10, 100) on average, per week.

148 Most clinicians reported that they usually prescribed iron supplements (N=201; 79%) and
149 multivitamin supplements (N=193; 76%). Only 33% (N=87) usually prescribe RUTF, while 13% (N=33)
150 reported they usually counselled their patients regarding their nutrition (**Figure 1**). When asked to
151 estimate the proportion of patients they had prescribed supplements to in the past week, clinicians

152 reported a median (IQR) of 17% (6%, 50%) for iron supplements, 25% (IQR: 5%, 70%) for MMS, and 0%
153 (0%, 1%) for RUTF.

154 The 201 clinicians who reported usual iron supplement prescription (**Table 2**) usually prescribed
155 iron supplements once daily (69%) for a median of 30 days (IQR: 28, 30). Patients' clinical condition
156 (53%) and laboratory test results (46%) were the primary reasons for prescribing the supplements. Pallor
157 was the most commonly considered clinical feature among non-pregnant adults (84%), children (87%)
158 and individuals co-infected with TB (82%), though other clinical signs and symptoms were considered
159 too. Only 82% of the clinicians believed that all pregnant PLHIV should receive iron supplements. The
160 overwhelming majority of clinicians (98%) considered hemoglobin tests when deciding whether to
161 prescribe, though they used a wide range of hemoglobin cutoffs to initiate iron supplements: <11 g/dl
162 (14%), <10 g/dl (27%), <8.5 g/dl (36%) or <7 g/dl (20%). They would recommend blood transfusion when
163 hemoglobin was lower than 7 g/dl (20%) or 8.5 g/dl (13%), or using other cutoffs in the presence of
164 suggestive clinical symptoms or signs (29%). In addition, 85% considered higher hemoglobin cutoffs
165 above which iron supplements should be discontinued.

166 The 193 clinicians who reported usual MMS prescription (**Table 3**) usually prescribed MMS
167 supplements once daily (55%) for a median of 14 days (IQR: 14, 30). Patients' clinical condition (84%)
168 was the primary reason for prescribing the supplements. In addition to pallor (50%), unlike for iron
169 supplements, clinicians considered other clinical signs more frequently when deciding whether to
170 prescribe MMS to non-pregnant adults: recent hair loss (42%), recent weight loss (31%), diarrhea (28%)
171 and nail deformities (25%). They considered these same signs more frequently for patients who were
172 pregnant, co-infected with TB or were children. 100% of respondents believed that all pregnant women
173 should receive MMS.

174 The 82 clinicians who reported usual RUTF prescription (**Table 4**) usually prescribed them as
175 twice daily dose (61%) for a median of 17 days (IQR: 4, 70). Patients' clinical condition (85%) and
176 laboratory test results (13%) were the primary reasons for prescribing the supplements. Recent weight
177 loss was the most commonly considered clinical feature among non-pregnant adults (84%), pregnant
178 adults (75%), children (100%) and individuals co-infected with TB (100%), though other clinical signs and
179 symptoms were considered too.

180 For all three types of supplements considered, clinicians were most concerned (approximately
181 20% or greater) about the need for frequent refills and of supplements being out-of-stock (**Figure 2**).
182 Some clinicians were concerned about the cost of the supplements. Infection risk (3%) and
183 contraindications (7%) were also concerns that a small number of clinicians had that influenced their
184 prescribing patterns for iron supplements.

185 Univariable models evaluating the relationships of multiple demographic and professional
186 characteristics with clinicians' prescription of nutritional interventions found that the clinicians who self-
187 reported attended to between 10 and <100 patients in the preceding week were more likely to
188 prescribe RUTF, compared to clinicians who attended to <10 patients weekly(**Supplementary table 1**).
189 No other significant relationships for iron, MMS or RUTF with demographic and professional factors was
190 found. Factors that were evaluated include the district, facility type, clinicians' age, qualification,
191 number of years since graduation, years since working at MDH, the number of patients seen in the last
192 week.

193 For each of non-pregnant adult, pregnant adult, TB-HIV coinfecting and pediatric populations,
194 univariable models evaluated the relationship of self-reported reasons for prescribing supplements and
195 clinicians' prescription of nutritional interventions. Clinicians who believed that all pregnant HIV patients

196 should receive iron supplements were 1.23-fold (95% CI: 1.03, 1.56) more likely to report prescribing
197 them(**Supplementary table 2**). No other significant relationships were identified.

198

199 Discussion

200 We conducted a survey of clinicians' prescription of iron supplements, MMS and RUTF
201 at HIV care and treatment centers in Dar es Salaam, and found that these nutritional
202 interventions were frequently recommended by clinicians to their patients. We identified the
203 common patterns of prescribing the different supplements, including the reasons for
204 prescribing, duration and dose. Most clinicians believed that pregnant HIV patients should
205 receive iron supplements and MMS. All clinicians believed that all patients coinfecting with TB
206 and HIV should receive MMS. Only 3% considered the presence of signs of infections to be
207 contraindications to iron supplements. Instead, clinicians were concerned that stockouts and
208 the need for frequent refills discourage them from prescribing iron supplements.

209 The overwhelming majority of clinicians in this network of HIV clinics reported that they
210 usually prescribe iron supplements to PLHIV. There are no current WHO guidelines for iron
211 supplementation among PLHIV due to concerns that iron supplementation may be unsafe or
212 ineffective in this context⁽¹⁷⁾. These concerns are based on the understanding that both iron
213 deficiency and iron overload may be associated with worsening immune function⁽²⁸⁾.
214 Epidemiological studies, including studies set in the same network of clinics as our survey, have
215 shown increased risk of mortality when iron status is elevated ^(18; 19; 20). These effects possibly

216 result from faster HIV replication, more frequent opportunistic infections, and oxidative
217 damage to tissues due to elevated iron status and higher levels of non-transferrin bound iron^{(29;}
218 ^{30; 31; 32)}. As shown in our study, clinicians self-report that they prescribe iron supplements to
219 PLHIV, possibly due to their concerns about iron deficiency. Iron deficiency is highly prevalent
220 (7% – 48%) among PLHIV^(18; 20; 33; 34). Severe iron deficiency leads to anemia, which also
221 increases mortality risk. Iron supplementation is well-known to be effective in the general
222 population to prevent and treat anemia^(35; 36; 37). Iron supplementation has however been
223 poorly studied among PLHIV^(21; 22; 23; 24). Clinicians who didn't prescribe iron supplements were
224 mostly concerned about stock-outs and frequent need for refills. Only few clinicians were
225 concerned about the infection-related risks. Nonetheless, well-designed studies are required to
226 evaluate the safety and effectiveness of iron supplementation among adult PLHIV to guide
227 clinical and public health decision making.

228 Most clinicians in our study also reported they frequently prescribed MMS. Only 13%
229 said they did not prescribe the previous week. Randomized trials and observational studies
230 among ART-naïve and ART-experienced individuals have demonstrated that MMS reduces the
231 risk of mortality, HIV disease progression, incident tuberculosis and immunologic failure^{(13; 38; 39;}
232 ⁴⁰⁾. Micronutrient deficiencies are very common among PLHIV; often with multiple concurrent
233 micronutrient deficiencies^(41; 42). These deficiencies result from increased food security risk,
234 reduced dietary intake due to anorexia, decreased nutrient absorption from systemic
235 inflammation, altered metabolism, and nutrient losses from diarrhea⁽⁴²⁾. Clinicians in our study
236 were more likely to prescribe MMS for therapeutic purposes and for short durations, to address
237 the effects of micronutrient deficiencies, rather than for prophylactic reasons. Only 20% of the

238 clinicians believed that MMS should be prescribed to all PLHIV. Clear evidence-based guidelines
239 regarding the use of MMS in HIV could potentially improve their appropriate use among PLHIV.

240 RUTF is effective to treat acute malnutrition among PLHIV on ART⁽⁴³⁾. Clinicians in our
241 study prescribed RUTF often, and 34% prescribed RUTF in the preceding week. The
242 prescriptions were often for guided by patients' clinical condition, especially in the presence of
243 recent weight loss or hair loss, and for durations lasting 30 days or less. No clinician
244 recommended universal use. Taken together, there seemed to be great alignment among
245 clinicians regarding whether and when to prescribe RUTF to their patients. There was less
246 alignment with iron and multiple micronutrient supplementation. The lack of global
247 recommendations or guidelines regarding the use of micronutrient supplements likely explains
248 the disparity. Possible alternative explanations may be that the clinicians perceive the
249 effectiveness of micronutrient supplements to be limited, relative to macronutrient RUTF
250 supplementation.

251 Clinicians were concerned about patient access for the supplements they intended to
252 prescribe. They were concerned about stockouts for all the supplements. Stockouts are a
253 common hindrance to the uptake and regular use of micronutrient supplementation in
254 developing countries^(44; 45; 46). Addressing these supply chain challenges could potentially
255 improve patients' quality of life, and reduce the risk of outcomes. Private facilities could play a
256 key role to fill the shortfall from the HIV care and treatment program⁽⁴⁷⁾. Clinicians were also
257 worried about the need for frequent refills, a result of the transient effect of these supplements
258 and the supply chain issues mentioned above. Only few clinicians were concerned about the

259 cost of the supplements, as iron and multivitamins tend to be cheap, and RUTF has been
260 provided free of charge to patients.

261 Our study has one important limitation. Participants were asked to self-report their
262 prescription patterns of micronutrient supplementation. Clinicians sometimes prescribed iron
263 and multiple micronutrient supplements without recording in the patients' health records,
264 especially when the patients have to purchase the supplements at private pharmacies.
265 Although RUTFs were always documented in the health records, the anonymous nature of the
266 survey makes it impossible to validate the prescribing patterns. It was also impossible to
267 confirm the clinical and laboratory indications for which supplements would have been
268 prescribed.

269 Conclusion

270 We conducted a cross-sectional survey among clinicians with prescribing responsibility at clinics
271 providing care to PLHIV in Dar es-Salaam, Tanzania. We found that substantial proportion
272 prescribe nutritional supplements, although there is a lot of variation in why they prescribe
273 them, and for how long. Clear guidelines regarding the prescription of nutritional supplements
274 may be necessary given the state of the evidence regarding the safety and effectiveness of the
275 supplements.

276

277

278

279

280 **Tables**

281 **Table 1. Participant characteristics, N=254**

Characteristic	N (%)
District	
Ilala	66 (26%)
Kigamboni	7 (3%)
Kinondoni	80 (31%)
Temeke	67 (26%)
Ubungo	34 (13%)
Facility type	
ANC	4 (2%)
CTC	162 (64%)
TB/HIV clinic	21 (8%)
Other	67 (26%)
Age	
Median (IQR)	43 (34, 49)
<30	32 (13%)
30 – <40	59 (25%)
40 - <50	54 (23%)
>50	94 (39%)
Qualification	
Clinical officer	166 (65%)
Medical assistant	54 (21%)
Medical doctor	34 (13%)
Number of years since graduation	
Median (IQR)	13 (5, 21)
1 – 10	111 (43%)
11 – 20	67 (26%)
21 – 30	58 (23%)
31 – 40	13 (5%)
41 – 50	4 (2%)
Years since starting working with PLHIV	
Median (IQR)	5 (2, 11)
0 – 5	132 (52%)
6 – 10	56 (22%)
11 – 16	66 (26%)
Number of patients seen previous week	
Median (IQR)	30 (10, 100)
<10	44 (18%)
10 - <30	76 (31%)
30 - <60	34 (14%)
60 - <100	27 (11%)
>100	67 (27%)

282


283

284

285

286

287 Figure 1. Proportion of clinicians who usually prescribed nutritional supplements



288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305

306 Table 2. Prescribing pattern for iron supplements (N=201)

Variable	n (%)
Number of patients prescribed iron supplements in the last week	
More than 20	22 (11%)
10 to 20	32 (16%)
5 to 9	138 (69%)
None	9 (5%)
Number of days of supplements prescribed	
Median	30 (28, 30)
4 – 14	45 (22%)
15 – 30	152 (76%)
31 – 60	0 (0%)
61 – 90	4 (2%)
Iron dose prescribed	
Once daily	139 (69%)
Twice daily	60 (30%)
Twice weekly	2 (1%)
Primary reason for prescribing iron supplements	
Patient or caretaker requests it	1 (0.5%)
Clinical condition warrants it	106 (53%)
Lab test results warrant it	92 (46%)
Other	2 (1%)
Clinical features that influence iron supplement use in non-pregnant adults with HIV	
Recent weight loss	32 (16%)
Pallor	168 (84%)
Recent hair loss	38 (19%)
Nail deformities	60 (30%)
Diarrhea	36 (18%)
All adult HIV patients should receive supplements	18 (9%)
None of the above	9 (5%)
Clinical features that influence iron supplement use in pregnant adults with HIV	
Recent weight loss	11 (6%)
Pallor	81 (43%)
Recent hair loss	4 (2%)
Nail deformities	17 (9%)
Diarrhea	5 (3%)
All pregnant HIV patients should receive supplements	154 (82%)
None of the above	4 (2%)
Clinical features that influence iron supplement use in TB coinfection	
Recent weight loss	50 (25%)
Pallor	158 (82%)
Recent hair loss	36 (19%)
Nail deformities	59 (31%)
Diarrhea	27 (14%)
All patients coinfecting with TB patients should receive supplements	36 (19%)
None of the above	6 (3%)
Clinical features that influence iron supplement use in children	
Recent weight loss	53 (27%)
Pallor	160 (87%)
Recent hair loss	41 (22%)
Nail deformities	48 (26%)
Diarrhea	38 (21%)

Variable	n (%)
All pediatric patients should receive supplements	33 (18%)
None of the above	0 (0%)
Clinician considers hemoglobin test to prescribe or discontinue iron supplements	
Yes	197 (98%)
Hemoglobin Cutoff below which iron supplements are initiated	
<7 g/dl	39 (20%)
<8.5 g/dl	71 (36%)
<10 g/dl	54 (27%)
<11 g/dl	27 (14%)
Others	7 (4%)
Lower cutoff below which iron supplements are discontinued and blood transfusion recommended instead	
<7 g/dl	41 (20%)
<8.5 g/dl	26 (13%)
<10 g/dl	26 (13%)
<11 g/dl	49 (24%)
Others	59 (29%)
Higher cutoff above which iron supplements discontinued	
Yes	168 (85%)

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325 Table 3. Prescribing pattern of multivitamin supplements (N=193)

Variable	N (%)
Number of patients prescribed MMS supplements in the last week	
More than 20	18 (9%)
10 to 20	31 (16%)
5 to 9	120 (62%)
None	25 (13%)
Number of days of supplements prescribed	
Median	14 (14, 30)
3 – 14	97 (50%)
15 – 30	92 (48%)
31 – 60	0 (0%)
61 – 90	4 (2%)
MMS dose prescribed	
Once daily	104 (55%)
Twice daily	85 (45%)
Twice weekly	2 (1%)
Primary reason for prescribing MMS supplements	
Patient or caretaker requests it	1 (1%)
Clinical condition warrants it	162 (84%)
Lab test results warrant it	30 (16%)
Clinical features that influence MMS supplement use in non-pregnant adults with HIV	
Recent weight loss	50 (31%)
Pallor	81 (50%)
Recent hair loss	69 (42%)
Nail deformities	41 (25%)
Diarrhea	45 (28%)
All adult HIV patients should receive supplements	32 (20%)
None of the above	17 (9%)
Clinical features that influence MMS supplement use in pregnant adults with HIV	
Recent weight loss	44 (23%)
Pallor	58 (64%)
Recent hair loss	43 (47%)
Nail deformities	32 (35%)
Diarrhea	33 (36%)
All pregnant HIV patients should receive supplements	91 (100%)
None of the above	15 (8%)
Clinical features that influence MMS supplement use in TB coinfection	
Recent weight loss	65 (34%)
Pallor	85 (77%)
Recent hair loss	54 (49%)
Nail deformities	41 (37%)
Diarrhea	40 (36%)
All patients coinfecting with TB patients should receive supplements	111 (100%)
None of the above	11 (6%)
Clinical features that influence MMS supplement use in children	
Recent weight loss	69 (37%)
Pallor	81 (59%)
Recent hair loss	47 (34%)
Nail deformities	30 (22%)
Diarrhea	39 (28%)
All patients coinfecting with TB patients should receive supplements	49 (36%)

None of the above	0 (0%)
Clinician considers hemoglobin test to prescribe or discontinue MMS supplements	
Yes	129 (68%)
Hemoglobin Cutoff below which MMS supplements are initiated	
<7 g/dl	18 (10%)
<8.5 g/dl	72 (41%)
<10 g/dl	37 (21%)
<11 g/dl	13 (7%)
Others	35 (20%)
Lower cutoff below which MMS supplements are discontinued and blood transfusion recommended instead	
<7 g/dl	95 (55%)
<8.5 g/dl	14 (8%)
<10 g/dl	2 (1%)
<11 g/dl	15 (9%)
Others	48 (28%)
Higher cutoff above which MMS supplements discontinued	
Yes	163 (85%)

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345 Table 4. Prescribing pattern of RUTF supplements (N=82)

Variable	N (%)
Number of patients prescribed RUTF supplements in the last week	
More than 20	5 (6%)
10 to 20	8 (10%)
5 to 9	56 (68%)
None	13 (16%)
Number of days of RUTF prescribed	
Median	17 (4, 70)
3 – 14	41 (50%)
15 – 30	39 (48%)
31 – 60	0 (0%)
61 – 90	2 (2%)
RUTF dose prescribed	
Once daily	32 (39%)
Twice daily	50 (61%)
Primary reason for prescribing RUTF supplements	
Patient or caretaker requests it	1 (1%)
Clinical condition warrants it	70 (85%)
Lab test results warrant it	11 (13%)
Clinical features that influence RUTF supplement use in non-pregnant adults with HIV	
Recent weight loss	33 (65%)
Pallor	28 (55%)
Recent hair loss	32 (63%)
Nail deformities	11 (22%)
Diarrhea	16 (31%)
All adult HIV patients should receive supplements	0 (0%)
None of the above	7 (8%)
Clinical features that influence RUTF supplement use in pregnant adults with HIV	
Recent weight loss	63 (75%)
Pallor	35 (60%)
Recent hair loss	33 (57%)
Nail deformities	10 (17%)
Diarrhea	16 (28%)
All pregnant HIV patients should receive RUTF	0 (0%)
None of the above	7 (8%)
Clinical features that influence RUTF supplement use in TB coinfection	
Recent weight loss	61 (100%)
Pallor	34 (62%)
Recent hair loss	37 (67%)
Nail deformities	10 (18%)
Diarrhea	22 (40%)
All patients coinfecting with TB patients should receive supplements	0 (0%)
None of the above	1 (1%)
Clinical features that influence RUTF supplement use in children	
Recent weight loss	56 (100%)
Pallor	28 (56%)
Recent hair loss	33 (66%)
Nail deformities	8 (16%)
Diarrhea	23 (46%)
All patients coinfecting with TB patients should receive supplements	0 (0%)
None of the above	0 (0%)

Clinician considers physical exam findings to prescribe or discontinue RUTF supplements	
Yes	77 (96%)
Physical exam findings that guide initiation of RUTF	
BMI too low	46 (56%)
WHZ scores suggest patient is wasted	20 (24%)
Weight too small	16 (20%)

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360


361

362

363

364

365 Figure 2. Barriers to prescribing nutritional supplements



366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385

Supplementary Table 1. Demographic and professional characteristics associated with clinician's prescription of nutritional interventions

	Iron			MMS			RUTF		
	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)
District									
Ilala	10 (15%)	56 (29%)	Ref	13 (14%)	53 (32%)	Ref	2 (11%)	64 (27%)	Ref
Kigamboni	2 (29%)	5 (3%)	1.01 (0.39, 2.16)	1 (1%)	6 (4%)	0.69 (0.21, 1.67)	1 (6%)	6 (3%)	4.71 (0.24, 43.9)
Kinondoni	28 (35%)	52 (27%)	0.88 (0.61, 1.27)	33 (37%)	47 (29%)	0.95 (0.66, 1.36)	7 (39%)	73 (31%)	2.89 (0.73, 18.9)
Temeke	21 (31%)	46 (24%)	1.04 (0.72, 1.50)	21 (23%)	46 (28%)	0.82 (0.55, 1.22)	4 (22%)	63 (27%)	1.97 (0.40, 13.9)
Ubungo	1 (3%)	33 (17%)	0.73 (0.43, 1.18)	22 (24%)	12 (7%)	0.92 (0.57, 1.45)	4 (22%)	30 (13%)	3.88 (0.80, 27.0)
Facility type									
ANC	3 (5%)	1 (11%)	1.28 (0.39, 3.03)	2 (2%)	2 (1%)	0.68 (0.11, 2.14)	0 (0%)	4 (2%)	NR
CTC	37 (60%)	125 (65%)	Ref	52 (58%)	110 (67%)	Ref	13 (72%)	149 (63%)	Ref
TB/HIV clinic	8 (13%)	13 (7%)	1.15 (0.69, 1.82)	8 (9%)	13 (8%)	1.12 (0.81, 1.53)	2 (11%)	65 (28%)	1.78 (0.43, 5.00)
Other	14 (23%)	53 (28%)	0.99 (0.71, 1.36)	28 (31%)	39 (24%)	1.17 (0.69, 1.86)	3 (17%)	18 (8%)	0.37 (0.06, 1.30)
Age									
<30	7 (12%)	25 (14%)	Ref	12 (14%)	20 (13%)	Ref	2 (13%)	30 (14%)	Ref
30 – <40	12 (21%)	42 (23%)	1.06 (0.84, 1.40)	23 (26%)	31 (21%)	0.93 (0.58, 1.51)	4 (25%)	50 (22%)	1.23 (0.17, 7.07)
40 - <50	25 (44%)	69 (38%)	1.06 (0.87, 1.39)	38 (43%)	56 (37%)	0.95 (0.62, 1.48)	7 (44%)	87 (8%)	1.46 (0.33, 7.12)
>50	13 (23%)	46 (25%)	1.04 (0.83, 1.37)	15 (17%)	44 (29%)	0.70 (0.43, 1.15)	3 (18%)	56 (25%)	1.46 (0.42, 6.59)
Qualification									
Clinical officer	39 (63%)	127 (66%)	Ref	60 (67%)	106 (65%)	Ref	12 (67%)	154 (65%)	Ref
Medical assistant	19 (31%)	35 (18%)	1.11 (0.79, 1.54)	18 (20%)	36 (22%)	0.88 (0.61, 1.26)	3 (17%)	51 (22%)	0.82 (0.28, 3.46)
Medical doctor	4 (7%)	30 (16%)	0.94 (0.60, 1.41)	12 (13%)	22 (13%)	0.89 (0.56, 1.34)	3 (17%)	31 (13%)	0.63 (0.12, 3.24)
Years since graduation									
1 – 9	27 (46%)	84 (44%)	Ref	43 (49%)	68 (42%)	Ref	8 (44%)	103 (44%)	0.97 (0.34, 3.08)
10 – 19	16 (27%)	51 (27%)	1.08 (0.77, 1.51)	24 (27%)	43 (26%)	0.95 (0.67, 1.34)	5 (28%)	62 (27%)	Ref
20 – 29	14 (24%)	44 (23%)	0.98 (0.68, 1.40)	16 (18%)	42 (26%)	0.92 (0.63, 1.33)	5 (28%)	53 (23%)	1.16 (0.34, 3.97)
30 – 39	2 (3%)	11 (6%)	1.09 (0.55, 1.96)	5 (6%)	8 (5%)	0.98 (0.48, 1.800)	0 (0%)	13 (6%)	NR
40 – 50	0 (0%)	2 (1%)	1.29 (0.21, 4.08)	0 (0%)	2 (1%)	1.28 (0.21, 4.03)	0 (0%)	2 (1%)	NR
Years since working in HIV care									
0 – 5	30 (48%)	102 (53%)	Ref	51 (57%)	81 (49%)	Ref	10 (56%)	122 (52%)	Ref
6 – 10	14 (23%)	42 (22%)	1.22 (0.86, 1.70)	19 (21%)	37 (23%)	0.91 (0.64, 1.28)	5 (28%)	61 (26%)	0.71 (0.16, 2.21)
11 – 16	18 (29%)	48 (25%)	1.13 (0.81, 1.57)	20 (22%)	46 (28%)	1.10 (0.77, 1.54)	3 (17%)	53 (23%)	1.00 (0.32, 2.69)
Number of patients seen preceding week									
<10	10 (17%)	34 (18%)	Ref	20 (23%)	24 (15%)	Ref	2 (12%)	42 (18%)	Ref
10 - <30	21 (35%)	55 (29%)	1.20 (0.78, 1.87)	26 (29%)	50 (31%)	1.04 (0.68, 1.60)	1 (6%)	75 (33%)	1.95 (1.03, 4.26)
30 - <60	4 (7%)	30 (16%)	1.12 (0.66, 1.90)	11 (12%)	23 (15%)	0.98 (0.58, 1.64)	5 (29%)	29 (13%)	2.10 (1.01, 4.78)
60 - <100	3 (5%)	24 (13%)	1.20 (0.68, 2.06)	11 (12%)	16 (10%)	1.19 (0.69, 2.00)	3 (18%)	24 (10%)	2.24 (1.04, 5.14)
>100	22 (37%)	45 (24%)	1.27 (0.82, 2.00)	21 (24%)	46 (29%)	1.00 (0.64, 1.56)	6 (35%)	61 (26%)	1.83 (0.94, 4.05)

Supplementary Table 2. Self-reported reasons for prescribing and their relationship with clinician's prescription of nutritional interventions

	Iron			MMS			RUTF		
	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)	Yes, n (%)	No, n (%)	Prev Ratio (95% CI)
Clinical features to that influence supplement use in non-pregnant adults with HIV									
Recent weight loss	32 (16%)	10 (19%)	0.95 (0.77, 1.12)	31 (16%)	11 (18%)	0.96 (0.77, 1.14)	14 (17%)	28 (17%)	1.02 (0.60, 1.57)
Pallor	168 (84%)	42 (81%)	1.06 (0.90, 1.32)	16 (84%)	50 (83%)	1.01 (0.85, 1.26)	71 (88%)	135 (81%)	1.41 (0.85, 2.70)
Recent hair loss	38 (19%)	12 (23%)	0.95 (0.78, 1.10)	37 (19%)	13 (22%)	0.96 (0.78, 1.14)	17 (21%)	32 (19%)	1.07 (0.67, 1.60)
Nail deformities	60 (30%)	12 (23%)	1.07 (0.93, 1.21)	56 (29%)	16 (27%)	1.03 (0.88, 1.19)	20 (25%)	51 (31%)	0.81 (0.52, 1.21)
Diarrhea	36 (18%)	14 (27%)	0.89 (0.72, 1.04)	34 (18%)	16 (27%)	0.87 (0.69, 1.04)	18 (22%)	30 (18%)	1.18 (0.75, 1.75)
All patients	18 (9%)	2 (4%)	NR	17 (9%)	3 (5%)	1.13 (0.86, 1.32)	7 (9%)	13 (8%)	1.07 (0.51, 1.82)
Clinical features that influence iron supplement use in pregnant adults with HIV									
Recent weight loss	11 (6%)	4 (8%)	0.92 (0.60, 1.15)	13 (7%)	2 (3%)	NR	4 (5%)	10 (6%)	0.86 (0.29, 1.70)
Pallor	81 (43%)	19 (40%)	1.03 (0.90, 1.17)	72 (40%)	28 (49%)	0.92 (0.78, 1.06)	36 (46%)	63 (41%)	1.12 (0.78, 1.60)
Recent hair loss	4 (2%)	3 (6%)	0.71 (0.28, 1.09)	5 (3%)	2 (4%)	0.94 (0.46, 1.26)	2 (3%)	5 (3%)	0.83 (0.16, 1.95)
Nail deformities	17 (9%)	5 (10%)	0.97 (0.71, 1.17)	17 (10%)	5 (9%)	1.02 (0.75, 1.24)	9 (11%)	12 (8%)	1.29 (0.69, 2.03)
Diarrhea	5 (3%)	3 (6%)	0.78 (0.45, 1.34)	5 (3%)	3 (5%)	0.82 (0.48, 1.41)	3 (4%)	5 (3%)	1.10 (0.32, 2.16)
All patients	154 (82%)	32 (67%)	1.23 (1.03, 1.56)	140 (79%)	46 (81%)	0.97 (0.83, 1.18)	62 (79%)	122 (80%)	0.93 (0.63, 1.49)
Clinical features that influence iron supplement use in TB coinfection									
Recent weight loss	50 (25%)	8 (15%)	NR	44 (23%)	14 (23%)	0.99 (0.82, 1.15)	18 (22%)	38 (23%)	0.97 (0.61, 1.45)
Pallor	158 (82%)	39 (81%)	1.01 (0.88, 1.24)	145 (80%)	52 (88%)	0.88 (0.76, 1.05)	62 (81%)	131 (82%)	0.92 (0.61, 1.53)
Recent hair loss	36 (19%)	6 (13%)	NR	32 (18%)	10 (17%)	1.01 (0.81, 1.19)	16 (21%)	25 (16%)	1.25 (0.77, 1.86)
Nail deformities	59 (31%)	7 (15%)	NR	52 (29%)	14 (24%)	1.06 (0.90, 1.23)	23 (30%)	41 (26%)	1.14 (0.75, 1.67)
Diarrhea	27 (14%)	6 (13%)	1.03 (0.83, 1.19)	22 (12%)	11 (19%)	0.97 (0.64, 1.07)	13 (17%)	19 (12%)	1.29 (0.76, 1.97)
All patients	36 (19%)	8 (17%)	1.03 (0.85, 1.18)	37 (20%)	7 (12%)	1.14 (0.96, 1.32)	15 (20%)	29 (18%)	1.06 (0.64, 1.61)
Clinical features that influence iron supplement use in children									
Recent weight loss	53 (27%)	7 (14%)	NR	48 (26%)	12 (21%)	1.06 (0.90, 1.23)	21 (26%)	37 (23%)	1.12 (0.73, 1.64)
Pallor	160 (87%)	44 (94%)	NR	152 (86%)	52 (95%)	NR	68 (88%)	132 (87%)	1.06 (0.64, 2.05)
Recent hair loss	41 (22%)	9 (19%)	1.04 (0.87, 1.19)	35 (20%)	15 (27%)	0.90 (0.72, 1.07)	17 (22%)	31 (21%)	1.06 (0.66, 1.59)
Nail deformities	48 (26%)	7 (15%)	NR	43 (24%)	12 (22%)	1.03 (0.86, 1.20)	19 (25%)	34 (23%)	1.08 (0.69, 1.60)
Diarrhea	38 (21%)	9 (19%)	1.02 (0.85, 1.17)	32 (18%)	15 (27%)	0.87 (0.68, 1.05)	20 (26%)	26 (17%)	1.39 (0.91, 2.01)
All pediatric patients	33 (18%)	5 (11%)	NR	34 (19%)	4 (7%)	NR	13 (17%)	25 (17%)	1.02 (0.59, 1.57)
Provides nutritional counseling									
Yes	3 (6%)	30 (15%)	NR	26 (14%)	7 (12%)	1.04 (0.82, 1.22)	11 (13%)	21 (13%)	1.02 (0.59, 1.57)
No	49 (94%)	171 (85%)	Ref	167 (87%)	53 (88%)	Ref	71 (87%)	146 (87%)	Ref

References

1. Frank TD, Carter A, Jahagirdar D *et al.* (2019) Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. *The lancet HIV* **6**, e831-e859.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2020) 90–90–90: good progress, but the world is off-track for hitting the 2020 targets.
3. Bassett IV, Coleman SM, Giddy J *et al.* (2017) Barriers to Care and 1-Year Mortality Among Newly Diagnosed HIV-Infected People in Durban, South Africa. *Journal of acquired immune deficiency syndromes (1999)* **74**, 432-438.
4. Anigilaje EA, Aderibigbe SA (2018) Mortality in a Cohort of HIV-Infected Children: A 12-Month Outcome of Antiretroviral Therapy in Makurdi, Nigeria. *Advances in Medicine* **2018**, 6409134.
5. Silverman RA, John-Stewart GC, Beck IA *et al.* (2019) Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study. *PLOS ONE* **14**, e0223411.
6. Haider BA, Spiegelman D, Hertzmark E *et al.* (2019) Anemia, iron deficiency, and iron supplementation in relation to mortality among HIV-infected patients receiving highly active antiretroviral therapy in Tanzania. *AJTM&H*.
7. Makubi A, Okuma J, Spiegelman D *et al.* (2015) Burden and determinants of severe anemia among HIV-infected adults: Results from a large urban HIV program in Tanzania, East Africa. *Journal of the International Association of Providers of AIDS Care (JIAPAC)* **14**, 148-155.
8. Abioye AI, Anderson C, Sudfeld CR *et al.* (2020) Anemia, iron status and HIV: A systematic review of the evidence. *Advances in Nutrition*.
9. Isanaka S, Mugusi F, Urassa W *et al.* (2012) Iron deficiency and anemia predict mortality in patients with tuberculosis. *The Journal of nutrition* **142**, 350-357.
10. O'Brien ME, Kupka R, Msamanga GI *et al.* (2005) Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. *Journal of acquired immune deficiency syndromes (1999)* **40**, 219-225.
11. Shivakoti R, Christian P, Yang W-T *et al.* (2016) Prevalence and risk factors of micronutrient deficiencies pre-and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. *Clinical Nutrition* **35**, 183-189.
12. Campa A, Yang Z, Lai S *et al.* (2005) HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **41**, 1179-1185.
13. Fawzi WW, Msamanga GI, Spiegelman D *et al.* (2004) A randomized trial of multivitamin supplements and HIV disease progression and mortality. *New England Journal of Medicine* **351**, 23-32.
14. Liu E, Spiegelman D, Semu H *et al.* (2011) Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. *The Journal of infectious diseases* **204**, 282-290.
15. Koethe JR, Chi BH, Megazzini KM *et al.* (2009) Macronutrient supplementation for malnourished HIV-infected adults: a review of the evidence in resource-adequate and resource-constrained settings. *Clinical Infectious Diseases* **49**, 787-798.
16. Chandrasekhar A, Gupta A (2011) Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? *Am J Clin Nutr* **94**, 1703S-1715S.
17. World Health Organization (WHO) (2004) Nutrient requirements for people living with HIV.

18. Haider BA, Spiegelman D, Hertzmark E *et al.* (2019) Anemia, Iron Deficiency, and Iron Supplementation in Relation to Mortality among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Tanzania. *Am J Trop Med Hyg.*
19. Abioye AI, Andersen CT, Sudfeld CR *et al.* (2020) Anemia, Iron Status, and HIV: A Systematic Review of the Evidence. *Advances in Nutrition* **11**, 1334-1363.
20. Noor RA, Abioye AI, Hertzmark E *et al.* (2020) Impaired Hematological Status Increases the Risk of Mortality among HIV-Infected Adults Initiating Antiretroviral Therapy in Tanzania. *The Journal of nutrition.*
21. Esan MO, van Hensbroek MB, Nkhoma E *et al.* (2013) Iron supplementation in HIV-infected Malawian children with anemia: a double-blind, randomized, controlled trial. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **57**, 1626-1634.
22. Semba RD, Ricketts EP, Mehta S *et al.* (2007) Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial. *Journal of acquired immune deficiency syndromes (1999)* **45**, 298-303.
23. Olsen A, Mwaniki D, Krarup H *et al.* (2004) Low-dose iron supplementation does not increase HIV-1 load. *Journal of acquired immune deficiency syndromes (1999)* **36**, 637-638.
24. Shet A, Bhavani PK, Kumarasamy N *et al.* (2015) Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. *BMC pediatrics* **15**, 164.
25. Fawzi WW, Msamanga GI, Kupka R *et al.* (2007) Multivitamin supplementation improves hematologic status in HIV-infected women and their children in Tanzania. *The American journal of clinical nutrition* **85**, 1335-1343.
26. Sudfeld CR, Buchanan A, Ulenga N *et al.* (2019) Effectiveness of a multivitamin supplementation program among HIV-infected adults in Tanzania. *AIDS (London, England)* **33**, 93-100.
27. Barasa AW, Odwori PO, Chepng'eno W *et al.* (2018) Willingness to Pay for Local Ready-to-Use Therapeutic Food for Malnutrition Management in Bungoma and Busia Counties, Kenya. *Africa Journal of Technical and Vocational Education and Training* **3**, 151-159.
28. Drakesmith H, Prentice AM (2012) Hepcidin and the iron-infection axis. *Science (New York, NY)* **338**, 768-772.
29. Mateos F, Gonzalez C, Dominguez C *et al.* (1999) Elevated non-transferrin bound iron in the lungs of patients with *Pneumocystis carinii* pneumonia. *The Journal of infection* **38**, 18-21.
30. Tanner R, O'Shea MK, White AD *et al.* (2017) The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. *Scientific reports* **7**, 43478.
31. Schumann K, Solomons NW, Romero-Abal ME *et al.* (2012) Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men. *Food Nutr Bull* **33**, 128-136.
32. Mancone C, Grimaldi A, Refolo G *et al.* (2017) Iron overload down-regulates the expression of the HIV-1 Rev cofactor eIF5A in infected T lymphocytes. *Proteome science* **15**, 1-10.
33. Kerkhoff AD, Wood R, Cobelens FG *et al.* (2014) Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. *BMC infectious diseases* **14**, 3860.
34. Ezeamama AE, Guwatudde D, Sikorskii A *et al.* (2018) Impaired Hematologic Status in Relation to Clinical Outcomes among HIV-Infected Adults from Uganda: A Prospective Cohort Study. *Nutrients* **10**.
35. Fernandez-Gaxiola AC, De-Regil LM (2019) Intermittent iron supplementation for reducing anaemia and its associated impairments in adolescent and adult menstruating women. *Cochrane Database of Systematic Reviews.*

36. Mantadakis E, Chatzimichael E, Zikidou P (2020) Iron deficiency anemia in children residing in high and low-income countries: risk factors, prevention, diagnosis and therapy. *Mediterranean Journal of Hematology and Infectious Diseases* **12**.
37. Haider BA, Olofin I, Wang M *et al.* (2013) Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *Bmj* **346**, f3443.
38. Sudfeld CR, Buchanan A, Ullenga N *et al.* (2019) Effectiveness of a multivitamin supplementation program among HIV-infected adults in Tanzania. *AIDS (London, England)* **33**, 93.
39. Baum MK, Campa A, Lai S *et al.* (2013) Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naïve, HIV-infected adults in Botswana: a randomized clinical trial. *Jama* **310**, 2154-2163.
40. Drain PK, Kupka R, Mugusi F *et al.* (2007) Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. *The American journal of clinical nutrition* **85**, 333-345.
41. Balfour L, Spaans JN, Fergusson D *et al.* (2014) Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-naïve persons with HIV. *PloS one* **9**, e85607.
42. Amare B, Moges B, Mulu A *et al.* (2015) Quadruple burden of HIV/AIDS, tuberculosis, chronic intestinal parasitoses, and multiple micronutrient deficiency in ethiopia: a summary of available findings. *BioMed Research International* **2015**.
43. Ahoua L, Umutoni C, Huerga H *et al.* (2011) Nutrition outcomes of HIV - infected malnourished adults treated with ready - to - use therapeutic food in sub - Saharan Africa: a longitudinal study. *Journal of the International AIDS Society* **14**, 2-2.
44. Maina-Gathigi L, Omolo J, Wanzala P *et al.* (2013) Utilization of folic acid and iron supplementation services by pregnant women attending an antenatal clinic at a regional referral hospital in Kenya. *Maternal and child health journal* **17**, 1236-1242.
45. Gueye AL, Pendame R, Ndiaye B *et al.* (2015) Assessment of the iron-folic acid supplement (IFAS) supply chain to improve distribution at community level in Dakar and Fatick regions, Senegal. *European Journal of Nutrition & Food Safety*, 1109-1109.
46. Janjua TA, Nawaz K, Haider Z *et al.* (2015) Intensified Monitoring of Vitamin A Supplementation Programs in Hard-to-Reach Districts and Urban Slums of Pakistan Results in Improved Coverage. *European Journal of Nutrition & Food Safety*, 492-493.
47. Young S, Ali SM, Beckham S (2009) The potential role of private pharmacies in maternal iron supplementation in rural Tanzania. *Food and nutrition bulletin* **30**, 16-23.